-
Alternative name
CDKN1B, CDKN4, KIP1, MEN1B, MEN4, P27, P27; KIP1, P27KIP1 antibody
-
Catalog
A006068
-
Size100μg
-
Formliquid
-
Purity≥95% as determined by SDS-PAGE
-
StoragePBS with 0.02% sodium azide and 50% glycerol pH 7.3 , -20℃ for 24 months (Avoid repeated freeze / thaw cycles.)
-
ClonalityPolyclonal Antibody
-
Host Rabbit
-
Species ReactivityHuman, Mouse
-
Applications Tested/SuitableELISA,WB,IP,IHC,IF
-
PurificationImmunogen affinity purified
-
Immunogencyclin-dependent kinase inhibitor 1B (p27, Kip1)
-
IHCImmunohistochemistry of paraffin-embedded human breast cancer tissue slide using A006068( P27; KIP1 Antibody) at dilution of 1:200 (under 10x lens). heat mediated antigen retrieved with Tris-EDTA buffer(pH9).
-
Western BlotNIH/3T3 cells were subjected to SDS PAGE followed by western blot with A006068( P27; KIP1 Antibody) at dilution of 1:600
-
Recommended dilutionWB : 1:200-1:2000
IP : 1:200-1:1000
IHC : 1:50-1:500
IF : 1:50-1:500
-
Product Description specificalCDKN1B, also named as P27 or KIP1, is a cyclin-dependent kinase inhibitor, which shares a limited similarity with CDK inhibitor CDKN1A/p21. P27 binds to and prevents the activation of cyclin E-CDK2 or cyclin D-CDK4 complexes, and thus controlling cell cycle progression at G1. The degradation of this protein, which is triggered by its CDK dependent phosphorylation and subsequent ubiquitination by SCF complexes, is required for the cellular transition from quiescence to the proliferative state. Downregulation of P27 has been implicated in the progression of several malignancies, including lung cancer, hepatocellular carcinoma, salivary cancer, oral squamous cell carcinomas, and gastric cancer.
-
Gene nameCDKN1B
-
Uniprot IDP46527
-
Calculated M.W.27 kDa
-
Observed M.W.27 kDa
-